Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation

Paulina Liberman; Meghan K. Berkenstock; Bryn M. Burkholder; Benjamin C. Chaon; Jennifer E. Thorne

doi:10.1080/09273948.2020.1749857

Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation

Paulina Liberman, Meghan K. Berkenstock, Bryn M. Burkholder, Benjamin C. Chaon, Jennifer E. Thorne

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Purpose: To report the outcomes of the escalation of adalimumab (ADA) dose for refractory ocular inflammatory diseases. Methods: A retrospective case series of 15 patients (29 eyes) diagnosed with ocular inflammatory disease, including uveitis and scleritis, which was not adequately controlled with standard, every other week ADA dosing, leading to an escalation to weekly dosing. Results: Ten of fifteen patients escalated to weekly ADA achieved control of their inflammation; neither of the two patients increased for control of cystoid macular edema (CME) had resolution and required regional corticosteroids. One patient discontinued weekly ADA due to serious infection. The median length of follow up was 12 months. Conclusion: Our series suggests that the escalation of ADA can be a useful strategy for treating recalcitrant ocular inflammation, but may not be adequate to treat refractory CME.

Original language	English (US)
Pages (from-to)	1564-1568
Number of pages	5
Journal	Ocular Immunology and Inflammation
Volume	29
Issue number	7-8
DOIs	https://doi.org/10.1080/09273948.2020.1749857
State	Published - 2021

Keywords

Adalimumab
escalation
interval
uveitis
weekly

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

Access to Document

10.1080/09273948.2020.1749857

Cite this

@article{2715bf042db34e3e9783ab5d456ddb31,

title = "Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation",

abstract = "Purpose: To report the outcomes of the escalation of adalimumab (ADA) dose for refractory ocular inflammatory diseases. Methods: A retrospective case series of 15 patients (29 eyes) diagnosed with ocular inflammatory disease, including uveitis and scleritis, which was not adequately controlled with standard, every other week ADA dosing, leading to an escalation to weekly dosing. Results: Ten of fifteen patients escalated to weekly ADA achieved control of their inflammation; neither of the two patients increased for control of cystoid macular edema (CME) had resolution and required regional corticosteroids. One patient discontinued weekly ADA due to serious infection. The median length of follow up was 12 months. Conclusion: Our series suggests that the escalation of ADA can be a useful strategy for treating recalcitrant ocular inflammation, but may not be adequate to treat refractory CME.",

keywords = "Adalimumab, escalation, interval, uveitis, weekly",

author = "Paulina Liberman and Berkenstock, {Meghan K.} and Burkholder, {Bryn M.} and Chaon, {Benjamin C.} and Thorne, {Jennifer E.}",

note = "Publisher Copyright: {\textcopyright} 2020 Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/09273948.2020.1749857",

language = "English (US)",

volume = "29",

pages = "1564--1568",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "7-8",

}

TY - JOUR

T1 - Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation

AU - Liberman, Paulina

AU - Berkenstock, Meghan K.

AU - Burkholder, Bryn M.

AU - Chaon, Benjamin C.

AU - Thorne, Jennifer E.

PY - 2021

Y1 - 2021

N2 - Purpose: To report the outcomes of the escalation of adalimumab (ADA) dose for refractory ocular inflammatory diseases. Methods: A retrospective case series of 15 patients (29 eyes) diagnosed with ocular inflammatory disease, including uveitis and scleritis, which was not adequately controlled with standard, every other week ADA dosing, leading to an escalation to weekly dosing. Results: Ten of fifteen patients escalated to weekly ADA achieved control of their inflammation; neither of the two patients increased for control of cystoid macular edema (CME) had resolution and required regional corticosteroids. One patient discontinued weekly ADA due to serious infection. The median length of follow up was 12 months. Conclusion: Our series suggests that the escalation of ADA can be a useful strategy for treating recalcitrant ocular inflammation, but may not be adequate to treat refractory CME.

AB - Purpose: To report the outcomes of the escalation of adalimumab (ADA) dose for refractory ocular inflammatory diseases. Methods: A retrospective case series of 15 patients (29 eyes) diagnosed with ocular inflammatory disease, including uveitis and scleritis, which was not adequately controlled with standard, every other week ADA dosing, leading to an escalation to weekly dosing. Results: Ten of fifteen patients escalated to weekly ADA achieved control of their inflammation; neither of the two patients increased for control of cystoid macular edema (CME) had resolution and required regional corticosteroids. One patient discontinued weekly ADA due to serious infection. The median length of follow up was 12 months. Conclusion: Our series suggests that the escalation of ADA can be a useful strategy for treating recalcitrant ocular inflammation, but may not be adequate to treat refractory CME.

KW - Adalimumab

KW - escalation

KW - interval

KW - uveitis

KW - weekly

UR - http://www.scopus.com/inward/record.url?scp=85085045397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085045397&partnerID=8YFLogxK

U2 - 10.1080/09273948.2020.1749857

DO - 10.1080/09273948.2020.1749857

M3 - Article

C2 - 32407246

AN - SCOPUS:85085045397

SN - 0927-3948

VL - 29

SP - 1564

EP - 1568

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 7-8

ER -

Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this